OverviewSuggest Edit

Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. The Company's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Brincidofovir is an experimental antiviral drug for the treatment of cytomegalovirus, adenovirus, smallpox, and ebolavirus infections. Brincidofovir is a prodrug of cidofovir. Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability.

TypePublic
Founded2000
HQDurham, US
Websitechimerix.com

Latest Updates

Employees (est.) (Dec 2019)43(-47%)
Revenue (FY, 2019)$12.5 M(+74%)
Share Price (Sept 2020)$2.5 (+2%)
Cybersecurity ratingAMore

Key People/Management at Chimerix

Michelle Berrey

Michelle Berrey

CEO

Chimerix Office Locations

Chimerix has an office in Durham
Durham, US (HQ)
2505 Meridian Pkwy
Show all (1)

Chimerix Financials and Metrics

Chimerix Revenue

Chimerix's revenue was reported to be $12.52 m in FY, 2019
USD

Revenue (Q2, 2020)

1.4m

Market capitalization (10-Sept-2020)

162.7m

Closing stock price (10-Sept-2020)

2.5

Cash (30-Jun-2020)

53.5m

EV

111.5m
Chimerix's current market capitalization is $162.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

4.4m4.0m10.8m5.7m4.5m7.2m12.5m

Revenue growth, %

(8%)166%(47%)

General and administrative expense

8.3m17.5m31.8m25.0m27.1m23.6m21.2m

R&D expense

24.7m45.4m97.2m58.6m49.4m55.2m42.3m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

110.0m128.5m20.6m51.5m18.5m81.1m16.9m

Accounts Receivable

248.0k106.0k2.4m1.6m1.7m330.0k1.2m

Prepaid Expenses

2.8m2.8m6.1m3.3m2.6m3.4m

Inventories

2.8m
USDQ1, 2013

Financial Leverage

-0.2 x
Show all financial metrics

Chimerix Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Chimerix Online and Social Media Presence

Embed Graph

Chimerix News and Updates

Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020

DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10, 2020…

Chimerix, Exclusive Licensee of Cantex' Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19

WESTON, Fla., April 29, 2020 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of cancer and other life-threatening diseases, today announced that Chimerix, Inc., to whom it licensed worldwide...

Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update

- Successful DSTAT End of Phase 2 Meeting with FDA Confirms Phase 3 Readiness; First Patient Visit Expected mid-2020 in 1L AML -

Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting

DURHAM, N.C., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known a…

Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update

– Final Data from Phase 2 Randomized Trial of DSTAT in First-line AML Support Enhanced Durability of Response, Event-free Survival and Overall Survival Benefit –

Chimerix to Announce Third Quarter 2019 Financial Results and Provide an Operational Update on November 5, 2019

DURHAM, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of innovative medicines to treat patients with cancer and other serious diseases, today announced that it will host a live conference call and audio we…
Show more

Chimerix Blogs

Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19

Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 Content Import Wed, 04/29/2020 - 07:01 Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19 Apr 29…

Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox

Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox Content Import Tue, 04/28/2020 - 16:31 Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Cou…

Chimerix to Present at Cowen and Company 40th Annual Health Care Conference

Chimerix to Present at Cowen and Company 40th Annual Health Care Conference Content Import Wed, 02/26/2020 - 08:02 Chimerix to Present at Cowen and Company 40th Annual Health Care Conference Feb 26, 2020 This release is a backfill from a News Wire …

Pratik Multani MD

Pratik Multani MD Paul.alfano@na… Mon, 02/24/2020 - 09:27 Pratik Multani MD Dr. Pratik Multani currently serves as Chief Medical Officer of ORIC Pharmaceuticals. Prior to joining ORIC, Dr. Multani served as Chief Medical Officer of Ignyta, which was acquired by Roche in 2017.…

Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors

Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors Content Import Mon, 02/24/2020 - 08:02 Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors Feb 24, 2020 This release is a backfill from a News Wire General …

Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020

DURHAM, N.C. , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25,
Show more

Chimerix Frequently Asked Questions

  • When was Chimerix founded?

    Chimerix was founded in 2000.

  • Who are Chimerix key executives?

    Chimerix's key executives are Michelle Berrey.

  • How many employees does Chimerix have?

    Chimerix has 43 employees.

  • What is Chimerix revenue?

    Latest Chimerix annual revenue is $12.5 m.

  • What is Chimerix revenue per employee?

    Latest Chimerix revenue per employee is $291.1 k.

  • Who are Chimerix competitors?

    Competitors of Chimerix include MyoKardia, Otonomy and Alimera Sciences.

  • Where is Chimerix headquarters?

    Chimerix headquarters is located at 2505 Meridian Pkwy, Durham.

  • Where are Chimerix offices?

    Chimerix has an office in Durham.

  • How many offices does Chimerix have?

    Chimerix has 1 office.